This morning, Enzolytics, Inc. (OTCMKTS: ENZC) reported progress on several initiatives and investors ate the news up.
ENZC stock opened at $0.1049 and saw steady buying throughout the day to the tune of 111 million shares over double their average daily volume. All this action led to a strong close up 34% to $0.135 per share.
After hitting a high of $0.82 per share in February, the stock has steadily declined. With several rallies thwarted over the past few months investors want to know, will this rally continue or was this just another flash in the proverbial pan?
In the report the company updated investors on initiatives relating to six major initiatives:
- Monoclonal Antibodies for Treatment of HIV
- Monoclonal Antibodies for treating Covid-19.
- SARS-CoV-2 (Coronavirus) Monoclonal Antibodies
- ITV-1 anti-HIV Therapeutics
- Production of Monoclonal Antibodies for HTLV-½
- Monoclonal Antibodies for HTLV-½
While the report was extremely promising, the real reason for the increase in investor interest could be from the company’s presentation at last week’s interactive online Emerging Growth Conference. With a bunch of new eyeballs on a company in a hot space (Coronavirus treatments), it’s easy to see why ENZC took off today.
Keep ENZC on your radar to see if this can continue.